LhRH-antagonist

Phase 3Small molecule

TTurku University Hospital

LhRH-antagonist is one of 4 small molecule programs targeting Gut Microbiota. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Gut MicrobiotaRecruiting

Gut MicrobiotaPhase 3

Recruiting

Competition

Competitive Landscape

5 competitors in Gut Microbiota

#DrugCompanyPhaseTrials

Xifaxan

SSalix

Phase 3

3 2

LhRH-antagonist

TTurku University Hospital

Phase 3

1 3

MS-20

MMicrobio Co Ltd

Preclinical

1 4

Application of SHB001

UUniversity of Zurich

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Post-ApprovalRecruiting

Gut Microbiota

NCT06001619

Clinical

Trials by Indication[1]

Gut Microbiota1 trial

Prostate Medication, Metabolism and Gut Microbiota

Recruiting·TTurku University Hospital·Phase 4·NCT06001619·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for LhRH-antagonist. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — LhRH-antagonist compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for LhRH-antagonist. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Turku University Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: TTurku University Hospital

LhRH-antagonist

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Gut Microbiota1 trial

References

Drug Info

Quick Facts

Related News